AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
AXIM BIOTECHNOLOGIES, INC.
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Axim Biotechnologies statistics
Financials through Dec 31, 2023, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Market Cap | $923.99K | $197.05M |
| Enterprise Value | $999.41K | $106.56M |
| PS Ratio | 23.38 | 3.93 |
Enterprise value
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| EV / Sales | 25.29 | 2.69 |
Income (trailing twelve months)
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Revenue | $39.52K | $57.94M |
| Operating Income | -$2.75M | -$21.44M |
| Pretax Income | -$8.06M | -$14.45M |
| Net Income | -$8.06M | -$22.46M |
| EBITDA | -$2.32M | -$16.91M |
| EPS (Diluted) | -$0.04 | -$0.83 |
Margins
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Operating Margin | -6961.0% | -44.5% |
| Pretax Margin | -20395.0% | -13.0% |
| Profit Margin | -20395.0% | -39.2% |
| EBITDA Margin | -5880.4% | -31.3% |
| FCF Margin | -2607.7% | -8.85% |
Returns
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Return on Assets (ROA) | -193.4% | -41.0% |
Growth
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 345.3% | 6.01% |
| Revenue Growth (5Y CAGR) | -27.4% | 6.42% |
Balance sheet
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $156.46K | $62.42M |
| Total Debt | $231.87K | $120.13M |
| Net Cash (Debt) | -$75.42K | $15.68M |
| Net Cash Per Share | -$0.00 | $0.65 |
| Equity (Book Value) | -$7.66M | $48.79M |
| Book Value Per Share | -$0.03 | $1.36 |
| Tangible Book Value | -$7.66M | $23.06M |
| Working Capital | -$5.82M | $75.77M |
Financial position
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Current Ratio | 0.03 | 3.30 |
| Quick Ratio | 0.03 | 2.39 |
| Interest Coverage | -19.65 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.03M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$1.03M | -$20.28M |
| FCF Per Share | -$0.00 | -$0.41 |
Efficiency
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $6.59K | $398.96K |
| Profits Per Employee | -$1.34M | -$732.08K |
| Employee Count | 6 | 73 |
Dividends and yields
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Earnings Yield | -872.3% | -21.2% |
| FCF Yield | -111.5% | -7.64% |
Shares
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Shares Outstanding | 301,959,000 | 59,128,900 |
| Float | 301,959,000 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
Taxes
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Axim Biotechnologies | Industry median |
|---|---|---|
| Altman Z-Score | -28.36 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Axim Biotechnologies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.